Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $106M | $-81M | $-81M | $-35M | -30.2% | 38.9% | -33.9% |
| 2024 | $76M | $-109M | $-123M | $-113M | -36.2% | 0.4% | 3.4% |
| 2023 | $76M | $-121M | $-119M | $-122M | -25.5% | -81.6% | -195.4% |
| 2022 | $412M | $142M | $124M | $131M | 25.2% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 412.48 | 76.01 | 76.30 | 105.96 |
| Operating Revenue | - | 412.48 | 76.01 | 76.30 | 105.96 |
| Operating Expense | - | 282 | 214.02 | 196.12 | 198.50 |
| Research And Development | - | 208.60 | 143.62 | 134.62 | 137 |
| Selling General And Administration | - | 73.40 | 70.40 | 61.50 | 61.50 |
| Total Expenses | - | 282 | 214.02 | 196.12 | 198.50 |
| Operating Income | - | 130.49 | -138.01 | -119.82 | -92.54 |
| Total Operating Income As Reported | - | 130.53 | -138.05 | -137.11 | -92.55 |
| EBITDA | - | 142.49 | -120.70 | -108.62 | -81.42 |
| Normalized EBITDA | - | 141.34 | -119.52 | -92.11 | -80.82 |
| EBIT | - | 130.49 | -138.01 | -119.82 | -92.54 |
| Interest Income | - | 3.60 | 19.70 | 19.94 | 13.35 |
| Net Interest Income | - | 3.60 | 19.70 | 19.94 | 13.35 |
| Other Non Operating Income Expenses | - | -0.04 | 0.29 | -0.22 | 0.05 |
| Other Income Expense | - | 1.11 | -0.89 | -16.73 | -0.56 |
| Interest Income Non Operating | - | 3.60 | 19.70 | 19.94 | 13.35 |
| Net Non Operating Interest Income Expense | - | 3.60 | 19.70 | 19.94 | 13.35 |
| Pretax Income | - | 135.23 | -119.24 | -116.61 | -79.75 |
| Tax Provision | - | 10.89 | -0.57 | 6.08 | 1.38 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0.09 | -0.01 | -3.47 | -0.13 |
| Net Income Continuous Operations | - | 124.34 | -118.67 | -122.70 | -81.13 |
| Net Income From Continuing And Discontinued Operation | - | 124.34 | -118.67 | -122.70 | -81.13 |
| Net Income From Continuing Operation Net Minority Interest | - | 124.34 | -118.67 | -122.70 | -81.13 |
| Net Income | - | 124.34 | -118.67 | -122.70 | -81.13 |
| Net Income Common Stockholders | - | 124.34 | -118.67 | -122.70 | -81.13 |
| Net Income Including Noncontrolling Interests | - | 124.34 | -118.67 | -122.70 | -81.13 |
| Normalized Income | - | 123.28 | -117.49 | -109.65 | -80.65 |
| Diluted NI Availto Com Stockholders | - | 124.11 | -118.67 | -122.56 | -81.33 |
| Basic Average Shares | - | 65.19 | 68.86 | 75.85 | 75.40 |
| Diluted Average Shares | - | 65.25 | 68.86 | 75.88 | 75.41 |
| Reconciled Depreciation | - | 12 | 17.30 | 11.19 | 11.11 |
| Total Unusual Items | - | 1.15 | -1.18 | -16.51 | -0.61 |
| Total Unusual Items Excluding Goodwill | - | 1.15 | -1.18 | -16.51 | -0.61 |
| Special Income Charges | - | 0 | 0 | -17.29 | 0 |
| Impairment Of Capital Assets | - | 0 | 0 | 17.29 | 0 |
| Gain On Sale Of Security | - | 1.15 | -1.18 | 0.78 | -0.61 |
| General And Administrative Expense | - | 73.40 | 70.40 | 61.50 | 61.50 |
| Other Gand A | - | 49.60 | 48.10 | 35.40 | 30.60 |
| Salaries And Wages | - | 23.80 | 22.30 | 26.10 | 30.90 |
| Otherunder Preferred Stock Dividend | 28.53 | 0.23 | - | - | - |
| Average Dilution Earnings | - | -0.23 | 0 | 0.14 | -0.20 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Zymeworks Inc.this co. | ZYME | $1.8B | -22.76 | 6.88 | -30.2% | -22.40 |
| Astrana Health, Inc. | ASTH | $1.9B | 83.46 | 2.41 | 2.9% | 18.67 |
| Stoke Therapeutics, Inc. | STOK | $1.9B | -272.47 | 5.32 | -2.0% | -95.36 |
| Pulse Biosciences, Inc. | PLSE | $1.9B | -25.62 | 23.12 | -90.2% | -23.61 |
| Maravai LifeSciences Holdings, Inc. | MRVI | $1.8B |
| - |
| - |
| - |
| - |
| - |
| -14.08 |
| 8.67 |
| -61.6% |
| -13.48 |
| Pediatrix Medical Group, Inc. | MD | $1.8B | 11.11 | 2.12 | 19.1% | 7.64 |
| Viridian Therapeutics, Inc. | VRDN | $1.8B | -5.34 | 3.10 | -58.1% | -4.95 |
| Vericel Corporation | VCEL | $1.8B | 110.33 | 5.14 | 4.7% | 60.29 |
| ANI Pharmaceuticals, Inc. | ANIP | $1.8B | 22.99 | 3.33 | 14.5% | 10.29 |
| Peer Median | - | 2.88 | 4.23 | 0.5% | 1.35 | |
Historically, Nov has averaged the highest return (+12.7%); Jan the lowest (-7.2%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.4%Negative MonthJan 2026: -14.43% | +3.4%Positive MonthFeb 2026: +3.37% | +7.5%Positive MonthMar 2026: +7.51% | +10.0%Positive MonthApr 2026: +9.98% | -8.8%Negative MonthMay 2026: -8.75% | +4.0%Positive MonthJun 2026: +4.02% | -16.1%Negative MonthJul 2026: -16.07% | +24.0%*Positive MonthAug 2026: +24.02% | — | — | — | — |
| 2025 | -0.3%Neutral MonthJan 2025: -0.27% | -8.2%Negative MonthFeb 2025: -8.22% | -11.1%Negative MonthMar 2025: -11.12% | +9.2%Positive MonthApr 2025: +9.24% | -12.1%Negative MonthMay 2025: -12.14% | +9.8%Positive MonthJun 2025: +9.80% | +0.1%Neutral MonthJul 2025: +0.08% | +17.9%Positive MonthAug 2025: +17.91% | +15.3%Positive MonthSep 2025: +15.33% | +11.7%Positive MonthOct 2025: +11.74% | +40.0%Positive MonthNov 2025: +39.95% | -1.4%Neutral MonthDec 2025: -1.42% |
| 2024 | +4.3%Positive MonthJan 2024: +4.33% | +10.8%Positive MonthFeb 2024: +10.79% | -12.4%Negative MonthMar 2024: -12.41% | -18.4%Negative MonthApr 2024: -18.44% | -1.2%Neutral MonthMay 2024: -1.17% | +0.4%Neutral MonthJun 2024: +0.35% | +22.9%Positive MonthJul 2024: +22.91% | +12.1%Positive MonthAug 2024: +12.14% | +7.0%Positive MonthSep 2024: +6.99% | +9.2%Positive MonthOct 2024: +9.16% | +2.8%Positive MonthNov 2024: +2.85% | +3.9%Positive MonthDec 2024: +3.90% |
| 2023 | +20.2%Positive MonthJan 2023: +20.23% | -13.0%Negative MonthFeb 2023: -13.02% | +10.0%Positive MonthMar 2023: +9.98% | -7.1%Negative MonthApr 2023: -7.08% | -2.0%Negative MonthMay 2023: -2.02% | +5.0%Positive MonthJun 2023: +4.98% | -13.7%Negative MonthJul 2023: -13.66% | -2.9%Negative MonthAug 2023: -2.95% | -12.4%Negative MonthSep 2023: -12.43% | +10.7%Positive MonthOct 2023: +10.73% | +26.4%Positive MonthNov 2023: +26.35% | +17.1%Positive MonthDec 2023: +17.14% |
| 2022 | -45.7%Negative MonthJan 2022: -45.70% | -18.7%Negative MonthFeb 2022: -18.65% | -9.5%Negative MonthMar 2022: -9.53% | -6.7%Negative MonthApr 2022: -6.72% | +10.0%Positive MonthMay 2022: +9.98% | -21.1%Negative MonthJun 2022: -21.13% | +10.2%Positive MonthJul 2022: +10.19% | +9.8%Positive MonthAug 2022: +9.76% | -4.1%Negative MonthSep 2022: -4.06% | +20.8%Positive MonthOct 2022: +20.81% | +3.9%Positive MonthNov 2022: +3.90% | +1.8%Neutral MonthDec 2022: +1.81% |
| 2021 | — | — | — | — | -4.1%Negative MonthMay 2021: -4.06% | +11.2%Positive MonthJun 2021: +11.19% | -7.5%Negative MonthJul 2021: -7.49% | +2.8%Positive MonthAug 2021: +2.80% | -12.0%Negative MonthSep 2021: -11.97% | -23.4%Negative MonthOct 2021: -23.38% | -9.6%Negative MonthNov 2021: -9.62% | -18.5%Negative MonthDec 2021: -18.50% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
